According to a report from CNBC.com (1), the U.S. Drug Enforcement Administration (DEA) has rescheduled GW Pharmaceuticals’ cannabidiol (CBD)-based drug, Epidiolex, to schedule V.
Highlights from the 2018 Cannabis Science Conference
Pure Cannabis Research AG and Pure Holding AG announced the establishment of the Cannabis Research Center (CRC) in early September 2018. The CRC, located in Switzerland, will reportedly facilitate cutting-edge research on cannabis.
Two U.S. Senators introduced legislation that would allow doctors at the VA to prescribe medical cannabis to veterans in the 31 states that have established medical-marijuana programs.
The Cannabis Science Conference, which took place August 28–29, 2018 in Portland, Oregon, saw another year of record-breaking attendance and exhibitors.
Cannabis Science and Technology magazine is seeking contributed manuscripts for the November 2018 and January 2019 issues.
The FDA released a statement this week about reports of severe illnesses and deaths resulting from the use of synthetic cannabinoid products that have been contaminated with brodifacoum.
The U.S. Food and Drug Administration (FDA) recently approved the drug Epidiolex, which contains cannabidiol (CBD), as an oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy—Lennox-Gastaut syndrome and Dravet syndrome—in patients two years of age and older (1).
EVIO Labs Florida (Broward County, Florida) was recently recognized for their participation in The Emerald Test (Emerald Scientific), which is an interlaboratory comparison and proficiency assessment for cannabis testing.